Buonerba C - Search Results

1

Oligometastatic Prostate Cancer: Is it Only a Matter of Perspective?

Di Lorenzo G, Buonerba C. Di Lorenzo G, et al. Among authors: buonerba c. Eur Urol. 2019 May;75(5):705-706. doi: 10.1016/j.eururo.2018.12.010. Epub 2018 Dec 24. Eur Urol. 2019. PMID: 30591352

2

Ten-year adjuvant treatment with somatostatin analogs in a patient with atypical carcinoid of the lung.

Buonerba C, Gallo C, Di Lorenzo G, Romeo V, Marinelli A. Buonerba C, et al. Anticancer Drugs. 2010 Apr;21(4):465-8. doi: 10.1097/CAD.0b013e32833688a2. Anticancer Drugs. 2010. PMID: 20075713

3

Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer.

Riccardi F, Di Lorenzo G, Buonerba C, Monaco G, Monaco R, Rizzo M, Scagliarini S, Scognamiglio F, Di Napoli M, Carteni' G. Riccardi F, et al. Among authors: buonerba c. World J Surg Oncol. 2010 Feb 5;8:8. doi: 10.1186/1477-7819-8-8. World J Surg Oncol. 2010. PMID: 20137082 Free PMC article.

4

Castration-resistant prostate cancer: current and emerging treatment strategies.

Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Sternberg CN. Di Lorenzo G, et al. Among authors: buonerba c. Drugs. 2010 May 28;70(8):983-1000. doi: 10.2165/10898600-000000000-00000. Drugs. 2010. PMID: 20481655 Review.

5

Efficacy of rituximab in gastric diffuse large B cell lymphoma patients.

Leopardo D, Di Lorenzo G, De Renzo A, Federico P, Luponio S, Buonerba C, Matano E, Merola G, Imbimbo M, Montesarchio E, Rea A, Merola MC, De Placido S, Palmieri G. Leopardo D, et al. Among authors: buonerba c. World J Gastroenterol. 2010 May 28;16(20):2526-30. doi: 10.3748/wjg.v16.i20.2526. World J Gastroenterol. 2010. PMID: 20503452 Free PMC article.

6

Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?

Gallo C, Buonerba C, Di Lorenzo G, Romeo V, De Placido S, Marinelli A. Gallo C, et al. Among authors: buonerba c. J Neurooncol. 2010 Nov;100(2):311-9. doi: 10.1007/s11060-010-0168-y. Epub 2010 Jun 17. J Neurooncol. 2010. PMID: 20556481

7

Docetaxel rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice.

Buonerba C, Palmieri G, Di Lorenzo G. Buonerba C, et al. Eur Urol. 2010 Oct;58(4):636-7. doi: 10.1016/j.eururo.2010.06.025. Epub 2010 Jun 23. Eur Urol. 2010. PMID: 20580484 No abstract available.

8

Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer.

Di Lorenzo G, Buonerba C, Faiella A, Rescigno P, Rizzo M, Autorino R, Perdonà S, Riccardi N, Scagliorini S, Scognamiglio F, Masala D, Ferro M, Palmieri G, Aieta M, Marinelli A, Altieri V, De Placido S, Cartenì G. Di Lorenzo G, et al. Among authors: buonerba c. BJU Int. 2011 Jan;107(2):234-9. doi: 10.1111/j.1464-410X.2010.09498.x. BJU Int. 2011. PMID: 20590545 Clinical Trial.

9

Kidney cancer: overall survival is an unsuitable primary end point.

Di Lorenzo G, Buonerba C. Di Lorenzo G, et al. Among authors: buonerba c. Nat Rev Urol. 2010 Jul;7(7):367-8. doi: 10.1038/nrurol.2010.84. Nat Rev Urol. 2010. PMID: 20616795

10

Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.

Di Lorenzo G, Buonerba C, Federico P, Rescigno P, Milella M, Ortega C, Aieta M, D'Aniello C, Longo N, Felici A, Ruggeri EM, Palmieri G, Imbimbo C, Aglietta M, De Placido S, Mirone V. Di Lorenzo G, et al. Among authors: buonerba c. Eur Urol. 2010 Dec;58(6):906-11. doi: 10.1016/j.eururo.2010.09.008. Epub 2010 Sep 24. Eur Urol. 2010. PMID: 20884115

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

185 results

Search Page